NCT06108492View on ClinicalTrials.gov

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

PHASE1RecruitingINTERVENTIONAL

Enrollment

170

Participants

Timeline

Start Date

November 28, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

September 30, 2027

Conditions

Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Interventions

DRUG

SHR-2005

"In dose Escalation: Four dose levels are preset. The administration cycle included 6 times of induction perfusion period and 15 times of maintenance perfusion period.~In indication Expansion: Indications will be selected to evaluate preliminary efficacy."

Trial Locations (1)

200032

RECRUITING

Fudan University Zhongshan Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY